EU and US Regulatory Update - Tykerb/Tyverb® (lapatinib)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzumab to treat patients with HER2 (ErbB2)-positive metastatic breast cancer.
Positive top-line result for UCB's Cimzia® in psoriatic arthritis
- Details
- Category: UCB
UCB intends to submit regulatory applications for Cimzia® (certolizumab pegol) in psoriatic arthritis, by end of 2012. Top-line results from the RAPID-PsA™ phase 3 study evaluating the efficacy and safety of Cimzia® in patients with adult onset active psoriatic arthritis (PsA) demonstrated a clinically relevant and statistically significant improvement.
Merck Establishes Joint Venture with Supera Farma
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Cristália and Eurofarma.
Lilly releases its most comprehensive corporate responsibility report
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has released its most comprehensive corporate responsibility report using the Global Reporting Initiative (GRI) framework, which is designed to help companies report on economic, environmental and social performance.
Bristol-Myers Squibb Completes Acquisition of Inhibitex, Inc.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company ("Bristol-Myers") for all of the outstanding shares of common stock of Inhibitex, Inc. (NASDAQ: INHX) ("Inhibitex") at a purchase price of $26.00 per share.
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.
Fifth Lilly Oncology on Canvas Art Competition invites all touched by cancer
- Details
- Category: Eli Lilly and Company
Get your canvases, paintbrushes and cameras ready - the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.
More Pharma News ...
- Sanofi fourth-quarter and full-year net sales
- Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
- Roche in 2011: Strong results and positive outlook
- AstraZeneca fourth quarter and full year results 2011
- Pfizer reports fourth-quarter and full-year 2011 results
- Novartis extends commitment to help achieve final elimination of leprosy
- Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion